cmi_logo.png
[Latest] Global Air Compressor Rental Market Size/Share Worth USD 8,221.1 Million by 2033 at a 6.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
December 10, 2024 01:30 ET | Custom Market Insights
Austin, TX, USA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Air Compressor Rental Market Size, Trends and Insights By Type (Rotary Screw,...
logo.jpg
Aalberts N.V.: Aalberts hosts 2024 capital markets day and sets 2030 objectives
December 10, 2024 01:30 ET | Aalberts N.V.
Utrecht, 10 December 2024 key highlights on track and committed to realise 2026 objectivesintroducing long-term 2030 objectivesdrive profitable sustainable growth and enhance leadership positions...
logo.jpg
Sampo plc cancels repurchased shares
December 10, 2024 01:30 ET | Sampo plc
Sampo plc, stock exchange release, 10 December 2024 at 8:30 am EET Sampo plc cancels repurchased shares Sampo plc has, in line with the decision by the Board of Directors, cancelled 11,747,690 own...
logo.jpg
Avance Gas Holding Ltd: Ex Dividend USD 3.50 today
December 10, 2024 01:01 ET | Avance Gas Holding Ltd
Hamilton, Bermuda. December 10, 2024. The shares in Avance Gas Holding Ltd (ticker: "AGAS") will be traded ex-dividend USD 3.50 as of today relating to the dividend for the third quarter of 2024. The...
Santhera Receives Po
Santhera Receives Positive Recommendation from NICE for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy
December 10, 2024 01:00 ET | Santhera Pharmaceuticals Holding AG
Santhera Receives Positive Recommendation from NICE for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy AGAMREE® has been recommended by NICE for treating Duchenne muscular...
VivoryonLogo1.jpg
Vivoryon Therapeutics N.V. Reports Q3 2024 Results and Highlights Progress on Varoglutamstat in Kidney Disease
December 10, 2024 01:00 ET | Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Reports Q3 2024 Results and Highlights Progress on Varoglutamstat in Kidney Disease Varoglutamstat Phase 2 program shows highly consistent, statistically significant and...
Kitron: Agility driv
Kitron: Agility driving growth and profits in 2025 and beyond
December 10, 2024 01:00 ET | Kitron ASA
(2024-12-10) Kitron is hosting a Capital Markets Presentation today to update investors on the company's financial and commercial targets and ambitions. There is strong growth in the Defence and...
Start of Day Message
December 10, 2024 01:00 ET | GlobeNewswire, Inc.
LONDON, 10 Dec. 2024 (GLOBE NEWSWIRE) -- This is the Start of Day Message for GlobeNewswire. GlobeNewswire is operated by Notified and is designated by the FCA as an approved primary information...
Melexis: Launch of s
Melexis: Launch of share buy-back program
December 10, 2024 01:00 ET | Melexis N.V.
Press release Regulated information – Inside information Ieper, Belgium - 10 December 2024, 07.00 hrs CET Melexis NV (Euronext Brussels: MELE) (“Melexis”) announces the launch of a share buy-back...
roche-logo-blue.png
New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma
December 10, 2024 01:00 ET | F. Hoffmann-La Roche Ltd
Long-term data confirm fixed-duration Columvi and Lunsumio achieve durable remissions beyond the end of treatment, with real-world data suggesting reduced treatment-related travel burden due to less...